Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

11.02 USD -0.84 (-7.08%)
Official Closing Price Updated: 6:03 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
- Five Phase 2 Programs in Four Orphan Indications 
From PR Newswire
Analysts Anticipate VTWG To Hit $129
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
Analysts Predict 10% Gains Ahead For The Holdings of EQWS
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BRIEF-Eiger Biopharmaceuticals may offer and sell shares of common stock of up to $25 mln
* May offer and sell shares of common stock of up to $25.0 million - SEC filing Source: (http://bit.ly/2k2lS09) Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger Completes $25 Million Debt Financing with Oxford Finance
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing... 
From PR Newswire
BRIEF-Eiger announces first patient dosed in open-label extension of phase 2 liberty study of ubenimex
* Eiger announces first patient dosed in open-label extension of phase 2 liberty study of Ubenimex in pulmonary arterial hypertension (pah) Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
First-in-class inhibitor of LTB4 targeting disease modification in PAH 
From PR Newswire
We Did The Math VTWG Can Go To $123
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Who Else Might Johnson & Johnson Seek To Acquire With Actelion Now Out Of Its Crosshairs?
Johnson & Johnson (NYSE: JNJ) has reportedly abandoned its buyout bid for Actelion Ltd (OTC: ALIOF). No Deal Johnson & Johnson ... 
Tags Movers Biotech RETA
From Benzinga
BRIEF-Eiger Biopharmaceuticals updates on hypoglycemia study
* Eiger biopharmaceuticals inc - clinical and regulatory advances in development of exendin 9-39 for treatment of post-bariatric hypoglycemia (pbh) 
Tags companyNews
From Reuters: Company News
Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
-- Positive Interim Data from Phase 2 Multiple-Ascending Dose Study 
From PR Newswire
Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)
- Exendin 9-39 investigational new drug (IND) application filed 
From PR Newswire
Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical stage biopharmaceuticals company focused on the development and commercialization of targeted therapies for rare diseases, announced today that... 
From PR Newswire
BRIEF-Eiger says additional LOWR HDV program data, clinical and regulatory plans
* Eiger announces additional LOWR HDV program data, clinical and regulatory plans at the American Association for the Study of Liver Diseases (AASLD) meeting 
Tags companyNews
From Reuters: Company News
Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
- Update on Data Presented and Analyst Meeting through Monday Evening 
From PR Newswire
BRIEF-Eiger announces positive phase 2 data for the study of liver diseases (AASLD)
* Eiger - low dose LNF + RTV with peg IFN achieves most rapid and profound viral load decline, with highest rate of HDV-RNA PCR-negativity on treatment 
Tags companyNews
From Reuters: Company News
Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
- Data Presented through Monday Morning 
From PR Newswire
BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.49
* As of sept 30, 2016, co had cash and cash equivalents of $56.3 million, compared to $4.8 million at december 31, 2015 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
- Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 
From PR Newswire
Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection
- Collaboration with ARUP Laboratories and Hepatitis B Foundation 
From PR Newswire
BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection
* Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus (HDV) infection 
Tags companyNews
From Reuters: Company News
Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study 
From PR Newswire
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted... 
From PR Newswire
Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the American Association... 
From PR Newswire
Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the... 
From PR Newswire
Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that... 
From PR Newswire
Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco. 
From GlobeNewswire News Releases
Hottest Manufacturing Stocks Now – BLDP NTAP TWIN DGLY
 
Tags NASDAQ:LITE NASDAQ:SPU NASDAQ:PERY
From InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.